Listing of Claims/Amendments

Please amend the claims to read as follows:

Claims 1-60 (previously canceled)

Claim 61 (previously presented): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl; or

R^5 and R^6 taken together with the carbon atom to form a carbonyl group;

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-

C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, $-OSO_2R^2$, $-COOR^2$, $-CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, $-CH_2-$, $-S(O_2)-$, or ;

Z is a covalent bond, $-CH_2-$, $-S(O_2)-$ or  ; or

Y, R^1, Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4,

with the proviso that, when $R^1 = R^2 = H$ or lower alkyl, Y=Z= covalent bond, n=0 or R^3 at each occurrence is H, $L^1 = L^2 = S$ or $-S(O_2)-$, X=H, and R^4 is unsubstituted C_1-C_6 alkyl or phenyl substituted once with $-CON(H)_2$ or $-CON(Me)_2$, then R^5 and R^6 are each independently H or C_1-C_6 alkyl.

Claim 62 (previously presented): A compound of the formula

L^1 is $-SO_2-$, -S- or -S(O)-;

L^2 is $-SO_2-$;

R^1 is H, CH_3NH-, $-CH_2CF_3$, $-NHC_3H_7$, $-NHC_2H_6$, $-NHC_4H_9$, C_1-C_6 alkyl, $-CF_3$, $-CH(CH_3)_2$, thiophenyl, morpholinyl, cyclopropyl, cyclopentyl, benzyl, naphthyl,
$-C(CH_3)_3$, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or $N(CH_3)_2$;

R^2 is H or $-CH_3$;

R^4 is C_1-C_6 alkoxyl, cyclohexyl, cyclopentyl, phenyl, tolyl, C_3H_7, trifluoromethoxyphenyl, or $-CH_3$; and

each R^4 may be optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

R^5 and R^6 are independently H or $-CH_3$;

X is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, halogen, $-CF_3$, $-OCH_3$, $-OCF_3$, $-OCF_2H$, $-CH_3$ or C_1-C_6 cycloalkyl;

Y is $-SO_2-$ or  ;

Z is a covalent bond; or

R^1, Y, R^2 and Z taken together with the nitrogen atom form a morpholinyl group.

Claim 63 (previously presented): The compound according to claim 62 wherein

L^1 is $-SO_2-$ or $-CH_2-$;

L^2 is $-SO_2-$;

R^1 is $-CH_3$ or $-CF_3$; and

R^4 is phenyl, optionally substituted with one to three substituents which are the same or different, and are independently selected from the group consisting of C_1-C_6 alkyl, C_1-C_6 alkoxy, OH, $-CF_3$ and halogen.

Claim 64 (previously presented): The compound according to claim 63 wherein R^4 is phenyl substituted with $-OCH_3$ or halogen.

Claim 65 (previously presented): The compound according to claim 64 wherein the halogen is selected from fluorine and chlorine.

Claim 66 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
A	$-OCH_3$	
B	$-OCH_3$	
C	$-OCF_2H$	
F	$-OCH_3$	
G	$-CH_3$	
I	$-OCH_3$	
J	$-OCF_3$	

	X	R^4
L	Cl	
O	Cl	
Q	CH_3	
Z	$-OCH_3$	
AA	$-OCH_3$	C_3H_7
AB	$-CF_3$	
AC	$-CF_3$	
AF	$-CF_3$	
AI	$-CF_3$	
AK	Cl	
AQ	Cl	

	X	R^4
AU	Cl	
AX	Cl	C_3H_7
BA	$-OCF_3$	
BB	$-OCF_3$	
BC	$-OCF_3$	
BG	$-OCH_3$	
CB	$-CH_3$	
CE	Cl	
CW	OH	
CX	OH	

	X	R^4
DA	$-OCF_2H$	
FR	H	
FS	H	
FT	H	
FW	H	

Claim 67 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R^4 are as shown in the table below:

	X	R^4
R	$-CF_3$	
S	Cl	
W	Cl	
AE	$-CF_3$	
AG	$-CF_3$	
AH	$-CF_3$	
AR	Cl	
AS	Cl	
BD	$-OCF_3$	

BJ	$-OCH_3$	
BZ	$-CH_3$	
CA	$-CH_3$	
FY	H	
FZ	H	
GI	Cl	
GJ	$-OCH_3$	
GL	OH	
GM	$OCH(CH_3)_2$	
GN		

Claim 68 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X, R^1 and R^4 are as shown in the table below:

	X	R^1	R^4
A	$-OCH_3$	$-CH_3$	
C	$-OCF_2H$	$-CH_3$	
G	$-CH_3$	$-CH_3$	
L	Cl	$-CH_3$	
R	$-CF_3$	$-CF_3$	

	X	R^1	R^4
S	Cl	$-CF_3$	
AB	$-CF_3$	$-CH_3$	
AT	Cl	$-N(CH_3)_2$	
BA	$-OCF_3$	$-CH_3$	
BD	$-OCF_3$	$-CF_3$	
BZ	$-CH_3$	$-CF_3$	
FS	H	$-CH_3$	
FY	H	$-CF_3$	
XXX		$-CF_3$	
XXXII	-CN	$-CF_3$	
XXXIII	$-NH_2$	$-CF_3$	

	X	R^1	R^4
XXXIV		$-CF_3$	
XXXIX	$-CONH_2$	$-CF_3$	
XXXX	$-OCH_3$	$-CF_3$	
XXXXI	-OH	$-CF_3$	
XXXII		$-CF_3$	
XXXIII		$-CF_3$	
XXXIV		$-CF_3$	
XXXXV		$-CF_3$	

Claim 69 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCH_3$ and R^1 is $-CH_3$.

Claim 70 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_2H$ and R^1 is $-CH_3$.

Claim 71 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CH_3$.

Claim 72 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CH_3$.

Claim 73 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CF_3$.

Claim 74 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CF_3$.

Claim 75 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CH_3$.

Claim 76 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-N(CH_3)_2$.

Claim 77 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CH_3$.

Claim 78 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CF_3$.

Claim 79 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CF_3$.

Claim 80 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CH_3$.

Claim 81 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CF_3$.

Claim 82 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is $-CF_3$.

Claim 83 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

Claim 84 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61 and a pharmaceutically acceptable carrier.

Claim 85 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 67 and a pharmaceutically acceptable carrier.

Claims 86-89 (canceled).

Claim 90 (previously presented): A pharmaceutical composition made by combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of a compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier therefor.

Claim 91–111 (canceled).

Claim 112 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCH_3$ and R^1 is $-CH_3$.

Claim 113 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_2H$ and R^1 is $-CH_3$.

Claim 114 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CH_3$.

Claim 115 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CH_3$.

Claim 116 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CF_3$.

Claim 117 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-CF_3$.

Claim 118 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CF_3$ and R^1 is $-CH_3$.

Claim 119 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-N(CH_3)_2$.

Claim 120 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CH_3$.

Claim 121 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-OCF_3$ and R^1 is $-CF_3$.

Claim 122 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-CH_3$ and R^1 is $-CF_3$.

Claim 123 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CH_3$.

Claim 124 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-CF_3$.

Claim 125 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is $-CF_3$.

Claim 126 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3.

Claim 127 (canceled).

Claim 128 (previously presented): A compound of the formula



or a pharmaceutically acceptable salt or stereoisomer thereof wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C_1-C_6 alkyl;

R^6 is H or C_1-C_6 alkyl; or

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, $-OSO_2R^2$, $-COOR^2$, $-CON(R^2)_2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, $-CH_2-$, $-S(O_2)-$, or  ;

Z is a covalent bond, $-CH_2-$, $-S(O_2)-$ or  ; or

Y, R^1, Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

Claim 129 (previously presented): A compound of the formula



or a pharmaceutically acceptable salt or stereoisomer thereof wherein:

R^1 is H, alkyl, haloC_1-C_6 alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_1-C_6 alkyl;

R^3 is H, C_1-C_6 alkyl, Cl, F, CF_3, OCF_2H, OCF_3, OH or C_1-C_6 alkoxy;

R^4 is H, C_1-C_6 alkyl, C_1-C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 and R^6 taken together with the carbon atom to form a carbonyl group;

L^1 is -$S(O_2)$-, -S(O)-, or -S-;

L^2 is -$S(O_2)$-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF_3, CN, OCF_2H, OCF_2CF_3, OCF_3, OR^2, C_1-C_6 alkyl, cycloalkyl, cycloalkoxy, C_1-C_6 alkoxy, alkoxyC_1-C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO_2R^2, -$COOR^2$, NHR^2, arylNH-, $N(R^2)_2$, or NR^2 aryl;

Y is a covalent bond, -CH_2-, -$S(O_2)$-, or  ; and

n is an integer of 0 to 4.